Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Negar Firouzabadi1, Roshanak Raeesi2, Kamiar Zomorrodian3, Ehsan Bahramali4, Ilnaz Yavarian2

1Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. Non communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. Yasuj University of Medical Sciences, Yasuj, Iran.
2Department of Pharmacology, School of Pharmacy, Shiraz University of Medical Sciences, International Branch, Shiraz, Iran.
3Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4Non communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Abstract


Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion: In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.


J Pharm Pharm Sci, 20 (0): 1-7, 2017

Full Text:

PDF


DOI: http://dx.doi.org/10.18433/J3W31F

Comments on this article

View all comments